INTERCEPT Program of Circulating Tumor DNA (ctDNA) Testing for Minimal ResidualDisease (MRD) in Colorectal Cancer (CRC): Results from a Pros Published Date January 22, 2024 Expand Fullscreen Exit Fullscreen Download PDF Expand Fullscreen
